Literature DB >> 21343261

Risk of herpes zoster among patients with chronic obstructive pulmonary disease: a population-based study.

Ya-Wen Yang1, Yi-Hua Chen, Kuo-Hsien Wang, Chen-Yi Wang, Hui-Wen Lin.   

Abstract

Background Systemic inflammation and dysregulated immune function in chronic obstructive pulmonary disease (COPD) is hypothesized to predispose patients to development of herpes zoster. However, the risk of herpes zoster among patients with COPD is undocumented. We therefore aimed to investigate the risk of herpes zoster among patients with COPD. Methods We conducted a cohort study using data from the Taiwan Longitudinal Health Insurance Database. We performed Cox regressions to compare the hazard ratio (HR) of herpes zoster in the COPD cohort and in an age- and sex-matched comparison cohort. We divided the patients with COPD into three groups according to use of steroid medications and performed a further analysis to examine the risk of herpes zoster. Results The study included 8486 patients with COPD and 33 944 matched control patients. After adjustment for potential confounding factors, patients with COPD were more likely to have incidents of herpes zoster (adjusted HR 1.68, 95% confidence interval [CI] 1.45-1.95). When compared with the comparison cohort, the adjusted HR of herpes zoster was 1.67 (95% CI 1.43-1.96) for patients with COPD not taking steroid medications. The adjusted HR of herpes zoster was slightly greater for patients with COPD using inhaled corticosteroids only (adjusted HR 2.09, 95% CI 1.38-3.16) and was greatest for patients with COPD using oral steroids (adjusted HR 3.00, 95% CI 2.40-3.75). Interpretation Patients with COPD were at increased risk of herpes zoster relative to the general population. The relative risk of herpes zoster was greatest for patients with COPD using oral steroids.

Entities:  

Mesh:

Year:  2011        PMID: 21343261      PMCID: PMC3060212          DOI: 10.1503/cmaj.101137

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  26 in total

1.  The Charlson comorbidity index (CCI) for adjustment of hip fracture mortality in the elderly: analysis of the importance of recording secondary diagnoses.

Authors:  Rômulo Cristovão de Souza; Rejane Sobrino Pinheiro; Cláudia Medina Coeli; Kenneth Rochel de Camargo
Journal:  Cad Saude Publica       Date:  2008-02       Impact factor: 1.632

Review 2.  Immunologic aspects of chronic obstructive pulmonary disease.

Authors:  Manuel G Cosio; Marina Saetta; Alvar Agusti
Journal:  N Engl J Med       Date:  2009-06-04       Impact factor: 91.245

3.  Defective natural killer and phagocytic activities in chronic obstructive pulmonary disease are restored by glycophosphopeptical (inmunoferón).

Authors:  A Prieto; E Reyes; E D Bernstein; B Martinez; J Monserrat; J L Izquierdo; L Callol; P de LUCAS; R Alvarez-Sala; J L Alvarez-Sala; V G Villarrubia; M Alvarez-Mon
Journal:  Am J Respir Crit Care Med       Date:  2001-06       Impact factor: 21.405

Review 4.  Bacterial infection and the pathogenesis of COPD.

Authors:  S Sethi
Journal:  Chest       Date:  2000-05       Impact factor: 9.410

5.  Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease.

Authors:  Gauree Gupta; Ebbing Lautenbach; James D Lewis
Journal:  Clin Gastroenterol Hepatol       Date:  2006-12       Impact factor: 11.382

Review 6.  The aging immune system and its relationship to the development of chronic obstructive pulmonary disease.

Authors:  Gulshan Sharma; Nicola A Hanania; Y Michael Shim
Journal:  Proc Am Thorac Soc       Date:  2009-12-01

Review 7.  Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis.

Authors:  M Bradley Drummond; Elliott C Dasenbrook; Marshall W Pitz; David J Murphy; Eddy Fan
Journal:  JAMA       Date:  2008-11-26       Impact factor: 56.272

8.  Use of high-dose inhaled corticosteroids is associated with pulmonary tuberculosis in patients with chronic obstructive pulmonary disease.

Authors:  Chin-Chung Shu; Huey-Dong Wu; Ming-Chih Yu; Jann-Tay Wang; Chih-Hsin Lee; Hao-Chien Wang; Jann-Yuan Wang; Li-Na Lee; Chong-Jen Yu; Pan-Chyr Yang
Journal:  Medicine (Baltimore)       Date:  2010-01       Impact factor: 1.889

9.  The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom.

Authors:  Allison L Smitten; Hyon K Choi; Marc C Hochberg; Samy Suissa; Teresa A Simon; Marcia A Testa; K Arnold Chan
Journal:  Arthritis Rheum       Date:  2007-12-15

10.  The impact of herpes zoster and post-herpetic neuralgia on quality-of-life.

Authors:  Robert W Johnson; Didier Bouhassira; George Kassianos; Alain Leplège; Kenneth E Schmader; Thomas Weinke
Journal:  BMC Med       Date:  2010-06-21       Impact factor: 8.775

View more
  35 in total

Review 1.  Prevention of Herpes Zoster and its complications: From clinical evidence to real life experience.

Authors:  Giovanni Gabutti; Paolo Bonanni; Michele Conversano; Guido Fanelli; Elisabetta Franco; Donato Greco; Giancarlo Icardi; Marzia Lazzari; Alessandro Rossi; Silvestro Scotti; Antonio Volpi
Journal:  Hum Vaccin Immunother       Date:  2016-12-07       Impact factor: 3.452

2.  Increased Health Care Resource Utilization and Costs Associated with Herpes Zoster Among Patients Aged ≥50 Years with Chronic Obstructive Pulmonary Disease in the United States.

Authors:  Parinaz Ghaswalla; Philippe Thompson-Leduc; Wendy Y Cheng; Colin Kunzweiler; Min-Jung Wang; Michael Bogart; Brandon J Patterson; Mei Sheng Duh; John Wojciehowski; Suna Park; Barbara P Yawn
Journal:  Chronic Obstr Pulm Dis       Date:  2021-10-28

3.  Increased risk of herpes zoster in children with asthma: a population-based case-control study.

Authors:  Bong-Seong Kim; Sonia Mehra; Barbara Yawn; Charles Grose; Robert Tarrell; Brian Lahr; Young J Juhn
Journal:  J Pediatr       Date:  2013-04-13       Impact factor: 4.406

4.  Sociodemographic characteristics and chronic medical conditions as risk factors for herpes zoster: a population-based study from primary care in Madrid (Spain).

Authors:  María D Esteban-Vasallo; M Felicitas Domínguez-Berjón; Ruth Gil-Prieto; Jenaro Astray-Mochales; Angel Gil de Miguel
Journal:  Hum Vaccin Immunother       Date:  2014-05-07       Impact factor: 3.452

5.  Combining Multiple Observational Data Sources to Estimate Causal Effects.

Authors:  Shu Yang; Peng Ding
Journal:  J Am Stat Assoc       Date:  2019-06-11       Impact factor: 5.033

6.  Risk of cancer among patients with herpes zoster infection: a population-based study.

Authors:  Yu-Ping Wang; Chia-Jen Liu; Yu-Wen Hu; Tzeng-Ji Chen; Yi-Tsung Lin; Chang-Phone Fung
Journal:  CMAJ       Date:  2012-09-17       Impact factor: 8.262

7.  TLR9 expression is required for the development of cigarette smoke-induced emphysema in mice.

Authors:  Robert F Foronjy; Matthias A Salathe; Abdoulaye J Dabo; Nathalie Baumlin; Neville Cummins; Edward Eden; Patrick Geraghty
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-06-10       Impact factor: 5.464

8.  Burden of Herpes Zoster in Adult Patients with Underlying Conditions: Analysis of German Claims Data, 2007-2018.

Authors:  Manuel Batram; Julian Witte; Magdalena Schwarz; Johannes Hain; Bernhard Ultsch; Maren Steinmann; Amit Bhavsar; Peter Wutzler; Carl-Peter Criée; Christiane Hermann; Klaus Wahle; Martin Füchtenbusch; Wolfgang Greiner
Journal:  Dermatol Ther (Heidelb)       Date:  2021-05-06

9.  Risk of herpes zoster in patients prescribed inhaled corticosteroids: a cohort study.

Authors:  Pierre Ernst; Sophie Dell'Aniello; Yann Mikaeloff; Samy Suissa
Journal:  BMC Pulm Med       Date:  2011-12-16       Impact factor: 3.317

10.  Cutaneous herpes zoster.

Authors:  Sharmila Sengupta
Journal:  Curr Infect Dis Rep       Date:  2013-10       Impact factor: 3.663

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.